Navigation Links
BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
Date:2/13/2013

HERNDON, Va., Feb. 13, 2013 /PRNewswire/ -- BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100.  The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.

BHR Pharma is sponsoring SyNAPSe with the intent to bring the first-ever approved TBI treatment to market.  The trial currently has 154 participating sites, including U.S. Level 1 and 2 trauma centers, in 21 countries on four continents. 

"Traumatic brain injury or TBI is a global problem that needs a global solution, and with providing an orphan drug designation for BHR-100 in Europe, the EMA acknowledges the importance of supporting the development of this potential treatment in TBI," said Roland Gerritsen van der Hoop , BHR Pharma Chief Medical Officer and Head of Global R&D. "BHR is committed to bringing this first-of-its-kind treatment to market with the hope of demonstrating progress in a condition with no approved therapies."

To qualify for orphan designation in Europe, a medicine must meet the following criteria:

  • The new medicine must be intended for the treatment, prevention or diagnosis of a disease that is life threatening or chronically debilitating;
  • The prevalence of the disease in the EU most not be more than five of every 10,000 people;
  • The new medicine must be of significant potential benefit to those affected by the disease.

In 2009, the U.S. Food and Drug Administration granted BHR-100 an Orphan Drug designation also for treating moderate and severe TBI and placed the drug on Fast Track status designed to accelerate its potential approval.

BHR initiated the SyNAPSe trial in June 2010 with a total enrollment target of 1,180 severe TBI patients. The trial is now more than 75 percent enrolled.  Last month, the SyNAPSe trial's Independent Data and Safety Monitoring Board (DSMB) released its formal interim analysis, concluding no safety issues exist, there was no reason to stop the study for futility and the trial may continue towards its intended completion. Patient enrollment is set to complete in 2013.

About Traumatic Brain Injury (TBI)
TBI is a serious public health problem that affects millions of people worldwide. There are approximately 66,000 deaths attributed annually to TBI in Europe.[1] According to the World Health Organization, traumatic brain injury is the leading cause of death and disability in children and young adults worldwide and is involved in nearly half of all trauma deaths. Despite significant efforts and more than 75 clinical trials over the past 20 years, there is still no approved treatment for TBI.

About BHR Pharma
Founded in January 2008, BHR Pharma, LLC (www.bhr-pharma.com) is a pharmaceutical research and development company located near Washington, DC, USA.  BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs. The company is a wholly owned subsidiary of Besins Healthcare SA (www.besins-healthcare.com), which markets healthcare products in 93 countries.

[1] Socin et al. JAMA273:22 (1995).


'/>"/>
SOURCE BHR Pharma, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... COSTA MESA, Calif. (PRWEB) , ... December 04, 2019 , ... ... of Mind and Medicine, an Orange County drug and alcohol rehab center ... Outreach Program! Members of their team conducted street outreach, trained, and distributed Naloxone amongst ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... for improved financial, operational and clinical health for our partners, today announced ... the American College of Healthcare Executives (ACHE). , ACHE is an international ...
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, a trusted resource for ... in Organizational Psychology Degree Programs for 2020. The comprehensive research guide is based ... program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... COMPLIANCY GROUP is ... the Wyoming Medical Society. Compliancy Group is dedicated to educating and assisting Wyoming ... to adhere to the standards set forth by the Health Insurance Portability and ...
(Date:12/6/2019)... ... December 06, 2019 , ... Dr. Scott Howell, a 2019 ... published research on the health benefits of coconut oil in the 7 November 2019 ... Effects on the Cardiometabolic Profile: A Structured Literature Review,” led by Dr. Hector O. ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... Risks and Rewards of Building Platforms— on Thursday, December 12, 2019, at 1:00 ... large, multi-specialty medical groups. Middle-market PE firms are scrambling to assemble regional platforms ...
(Date:12/5/2019)... ... December 05, 2019 , ... Today at M Health Fairview ... newest staff member who will to help them take medicine, relax during anxious ... procedures.  , Rocket, presented by NutriSource® is a golden retriever and the first ...
(Date:12/4/2019)... ... December 04, 2019 , ... WEDI , the nation’s leading ... information exchange and a trusted advisor to the U.S. Department of Health and Human ... was announced during the 2019 WEDI Winter Conference in Arlington, Va. on Wednesday, December ...
Breaking Medicine News(10 mins):